Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X about a paper by Naruhiko Ikoma et al. published in Annals of Surgery:
“Good read. Conditional recurrence analysis (i.e., future risk, given survival so far) suggests modern neoadjuvant therapy shifts recurrence later in pancreatic ductal adenocarcinoma (PDAC).
Overall survival (OS) gains driven by better post-recurrence OS (PROS).
PROS and conditional survival endpoints may better capture disease course and local therapy impact versus disease-free survival (DFS).”
Title: Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer
Authors: Samuel Cass, Ching-Wei Tzeng, Laura Prakash, Jessica Maxwell, Rebecca Snyder, Michael Kim, Ryan Huey, Brandon Smaglo, Shubham Pant, Eugene Koay, Robert Wolff, Jeffery Lee, Matthew Katz, Naruhiko Ikoma
You can read the full article in Annals of Surgery.
More posts about PDAC.